初次全关节置换术前使用GLP-1类似物与再入院及并发症风险降低相关
本研究基于TrinetX研究网络2005年5月至2023年12月84家医疗机构数据,纳入268,504例全髋关节置换(THA)和386,356例全膝关节置换(TKA)患者,按术前是否使用GLP-1受体类似物(GLP-1 RAs)分层并行1:1倾向评分匹配。结果显示,GLP-1 RA使用与THA后90天假体周围关节感染风险降低(2.1% vs 3.6%,RR=0.58,P=.042)及TKA后再入院风险降低(1.1% vs 2.0%,RR=0.53,P=.017)相关,其他结局无差异。作者认为GLP-1 RAs在择期关节置换患者中可能安全,但需进一步研究以指导常规使用。
要点
- THA术前使用GLP-1 RA与90天假体周围关节感染风险降低相关(2.1% vs 3.6%,RR=0.58,P=.042)。
- TKA术前使用GLP-1 RA与90天再入院风险降低相关(1.1% vs 2.0%,RR=0.53,P=.017)。
- 其他结局(包括误吸)风险无差异,作者认为GLP-1 RAs可能安全,但需进一步研究。
核心结论
- 术前使用GLP-1 RA与THA后90天假体周围关节感染风险降低42%相关,与TKA后90天再入院风险降低47%相关,其他风险(包括误吸)无差异。
- 作者认为GLP-1 RAs在择期关节置换患者中可能安全,但需进一步研究以指导其常规用于THA和TKA患者的体重管理。
研究设计与样本
- 基于TrinetX研究网络的回顾性队列研究,纳入2005年5月至2023年12月84家医疗机构中所有接受初次THA或TKA的患者。
- 按术前GLP-1 RA使用分层,行1:1倾向评分匹配以校正人口学、实验室检查和合并症基线差异,随后评估术后结局的风险比。
主要发现
- 共268,504例THA和386,356例TKA患者,其中术前使用GLP-1 RAs者分别为1,044例和2,095例。
- 匹配后,GLP-1 RA使用与THA后90天假体周围关节感染风险降低相关(2.1% vs 3.6%,RR=0.58,P=.042)。
- 匹配后,GLP-1 RA使用与TKA后90天再入院风险降低相关(1.1% vs 2.0%,RR=0.53,P=.017)。
- 比较组间所有其他结局的风险无差异。
临床怎么用
- 作者认为GLP-1 RAs在择期关节置换患者中可能安全,但需进一步研究以指导其常规用于THA和TKA患者的体重管理。
局限性
- 原文结论指出需进一步研究以指导GLP-1 RAs在THA和TKA患者体重管理中的常规使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There has been considerable interest in the use of GLP-1 receptor analogs (GLP-1 RAs) for weight optimization in patients undergoing elective arthroplasty. As there is limited data regarding the implications of their use, our study aimed to evaluate the association between preoperative GLP-1 RA use and postoperative outcomes in patients undergoing primary total hip arthroplasty (THA) and total knee arthroplasty (TKA). METHODS: The TrinetX research network was queried to identify all patients undergoing primary THA or TKA between May 2005 and December 2023 across 84 health care organizations. Patients were stratified based on preoperative GLP-1 RA use. Propensity score matching (1:1) was performed to account for baseline differences in demographics, laboratory investigations, and comorbidities. Subsequently, risk ratios were evaluated for postoperative outcomes. RESULTS: A total of 268,504 and 386,356 patients underwent THA and TKA, of which 1,044 and 2,095 used preoperative GLP-1 RAs. After matching, GLP-1 RA use was associated with a decreased 90-day risk of periprosthetic joint infection (2.1 versus 3.6%, RR = 0.58, P = .042) and readmission (1.1 versus 2.0%, RR = 0.53, P = .017) following THA and TKA, respectively. There was no difference in the risk of all other outcomes between comparison groups. CONCLUSIONS: Preoperative GLP-1 RA use is associated with a 42% decreased risk of periprosthetic joint infection and 47% decreased risk of readmission in the 90-day postoperative period following THA and TKA, respectively, with no difference in other risks, including aspiration. Our findings indicate that GLP-1 RAs may be safe to use in patients undergoing elective arthroplasty; however, further studies are warranted to inform the routine use of GLP-1 RAs for weight management in THA and TKA patients.
引用
- Buddhiraju A, Kagabo W, Khanuja HS, et al. Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty. J Arthroplasty. 2024. PMID: 38823516. doi:10.1016/j.arth.2024.05.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。